超重/肥胖人群的血浆致动脉硬化指数与新发糖尿病的相关性

摘要/Abstract

摘要： 目的探讨超重/肥胖人群中血浆致动脉硬化指数（AIP）与新发糖尿病的关联。方法采用队列研究方法,选取公开的中国人群队列研究中的超重/肥胖人群为研究对象,计算AIP并根据四分位数将其分为四组,采用Cox比例风险模型估计不同AIP组别的糖尿病发病风险及95%CI,并进行亚组分析。结果平均3.1年随访后,共新发糖尿病1 927例,Q1-Q4各组累积发病率分别为2.38%、3.33%、4.53%、6.10%,差异有统计学意义（P<0.01）。Cox比例风险模型分析显示,多因素校正后,AIP每增加0.1,糖尿病发病风险增加4%。与AIP Q1组相比,Q3与Q4组观察对象糖尿病发病风险分别增加至其1.28（95%CI 1.10-1.49）倍和1.37（95%CI 1.18-1.58）倍。（P均<0.001,趋势P值均<0.05）。结论 AIP与糖尿病发病率呈正向关联,高AIP是超重/肥胖人群发生糖尿病的危险因素之一。

杨晓玲, 陈瑞萍. 超重/肥胖人群的血浆致动脉硬化指数与新发糖尿病的相关性[J]. 心血管病防治知识, 2024, 14(6): 48-51.

参考文献

[1] Li Y, Teng D, Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997.
[2] 《中国居民营养与慢性病状况报告(2020年)》:我国超过一半成年居民超重或肥胖[J] . 中华医学信息导报, 2020, 35(24): 15.
[3] Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018,14(2):88-98.
[4] Dobiásová M.AIP atherogenic index of plasma as a significantpredictor of cardiovascular risk: from research to practice[J]. Vnitr Lek,2006,52(1):64-71.
[5] Nam JS, Kim MK, Park K,et al. The Plasma Atherogenic Index is an Independent Predictor of Arterial Stiffness in Healthy Koreans[J]. Angiology, 2022,73(6):514-519.
[6] Huang Q, Liu Z, Wei M,et al.The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China[J]. Cardiovasc Diabetol, 2023,22(1):125.
[7] Kim SH, Cho YK, Kim YJ,et al. Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: a nationwide population-based cohort study[J]. Cardiovasc Diabetol, 2022,21(1):81.
[8] Fu L, Zhou Y, Sun J,et al. Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus[J]. Cardiovasc Diabetol, 2021,20(1):201.
[9] Li YW, Kao TW, Chang PK, et al. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study[J]. Sci Rep, 2021,11(1):9900.
[10] Shi Y, Wen M.Sex-specific differences in the effect of the atherogenic index of plasma on prediabetes and diabetes in the NHANES 2011-2018 population[J]. Cardiovasc Diabetol, 2023,22(1):19.
[11] Chen Y, Zhang XP, Yuan J, et al.Association of body mass index and age with incident diabetes in Chinese adults: a population-based cohort study[J].BMJ Open, 2018,8(9):e021768.
[12] 中国超重肥胖医学营养治疗专家共识编写委员会.中国超重/肥胖医学营养治疗专家共识(2016年版)[J].中华糖尿病杂志, 2016, 8(9): 525-540.
[13] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409.
[14] 方伟,李尉键,蔡泽锋,等. 超重/肥胖人群的脉压与新发糖尿病的关联研究. 中华内分泌代谢杂志,2021, 37(8): 702-708.
[15] Wang C, Li J, Xue H, et al.Type 2 diabetes mellitus incidence in Chinese: contributions of overweight and obesity[J]. Diabetes Res Clin Pract. 2015,107(3):424-32.
[16] Yin B, Wu Z, Xia Y, et al.Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study[J]. Cardiovasc Diabetol, 2023,22(1):157.
[17] 方堃,丁岩,霍康. 超重/肥胖与血浆致动脉粥样硬化指数及其交互作用对45岁及以上人群2型糖尿病患病风险的影响[J]. 郑州大学学报(医学版),2023,4:489-493.
[18] Hirano T.Pathophysiology of Diabetic Dyslipidemia[J]. J Atheroscle Thromb, 2018,25(9):771-782.
[19] Xepapadaki E, Nikdima I, Sagiadinou EC,et al.HDL and type 2 diabetes: the chicken or the egg?[J].Diabetologia,2021, 64(9): 1917-1926.
[20] Jin X, Yang S, Lu J, et al.Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies[J]. Front Cardiovasc Med, 2022, 8:804214.
[21] Rohm TV, Meier DT, Olefsky JM,et al.Inflammation in obesity, diabetes, and related disorders[J]. Immunity, 2022,55(1):31-55.
[22] Kaur R, Kaur M, Singh J.Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies[J]. Cardiovasc Diabetol,2018,17(1):121.
[23] Xu S, Ilyas I, Little PJ, et al.Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies, Pharmacol Rev, 2021,73(3):924-967.